Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GGH | Q92820 | 1/20 | 0.56 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698067 | 1.00 | CA2 (0.67) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL97498 | 1.00 | CA2 (0.67) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28286177 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28184998 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28287497 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28286179 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28185002 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL4618531 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28375957 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28287499 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210307325-A1 | COMPOUNDS AND METHODS OF REDUCING NEMATODE INFECTION IN PLANTS | SONG BAO HUA (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200345006-A1 | METHODS OF REDUCING NEMATODE INFECTION IN PLANTS | UNIV NORTH CAROLINA CHARLOTTE (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3615084-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200412-A1 | MEMBRANE ACTIVE MOLECULES | BraneQuest, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-4072711-A | ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1978-02-07 | — | — | US | disclosed |
| US-4062856-A | ANIMAL GROWTH REGULATOR, HERBICIDE | AMERICAN CYANAMID CO. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4051183-A | 1-BENZOYL-3-(1,2,3,4-TETRAHYDRO-4-OXO-1-NAPHTHYL)-UREA, A NOVEL AND USEFUL INTERMEDIATE FOR THE PREPARATION OF ANIMAL GROWTH PROMOTING AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4041070-A | ANIMAL GROWTH PROMOTERS, ENHANCING FEED EFFICIENCY | AMERICAN CYANAMID COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-4036979-A | ANIMAL GROWTH RATE ACCELERATOR | AMERICAN CYANAMID COMPANY (US) | 1977-07-19 | — | — | US | disclosed |
| US-4005140-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3994924-A | ANIMAL GROWTH PROMOTERS | AMERICAN CYANAMID COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3993677-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3953506-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3953606-A | ANIMAL GROWTH STIMULATORS | AMERICAN CYANAMID COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CA2 1887/4885CA1 1312/4885TDP1 349/4885 |
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | CA2 519/4885CA1 240/4885TDP1 3276/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CA2 1887/4885CA1 1312/4885TDP1 349/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | CA2 519/4885CA1 240/4885TDP1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.